Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

In the current study, the researchers used what is known as fragment-based drug design instead. The method involves first ...

Isomorphic Labs is the secretive AI life science startup spun out of Google DeepMind with the goal of solving all disease ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery Center Photo 1 Left to Right: Ethan Grimes, BS, and Paul Morgan, MD, conduct ...

The event, held in the emblematic Casa de Convalescència, was supported by the BBVA Foundation and welcomed 150 international attendees. The conference addressed how advanced AI models and generative ...

The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials. Isomorphic Labs was ...

This work, published in Nature, uncovered the structural basis for understanding how α-Klotho interacts with the endocrine FGFs, opening up new avenues for structure-based drug design.

Presently departmental laboratories are devoted toward drug design, synthesis, and characterization. Additionally there is also a strong effort placed in protein receptor characterization and protein ...

The company is building what it describes as an AI drug design engine. The software reduces the amount of manual work involved in developing new medicines and thereby speeds up the process.

Azor Biotek is applying artificial intelligence solutions to the design and development of tailored, highly specific, novel small molecules, tapping into the vast potential of RNA drug targets.